PT - JOURNAL ARTICLE AU - Jones, Jacqueline AU - Stanbury, Mary AU - Haynes, Sandra AU - Bunting, Karina V AU - Lobban, Trudie AU - Camm, A John AU - Calvert, Melanie J. AU - Kotecha, Dipak AU - on behalf of the RAte control Therapy Evaluation in permanent Atrial Fibrillation (RATE-AF) trial group TI - Importance and assessment of quality of life in symptomatic permanent atrial fibrillation: Patient focus groups from the RATE-AF trial AID - 10.1101/2020.08.21.20179077 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.21.20179077 4099 - http://medrxiv.org/content/early/2020/08/23/2020.08.21.20179077.short 4100 - http://medrxiv.org/content/early/2020/08/23/2020.08.21.20179077.full AB - Aims To establish the extent and impact of symptoms in patients with atrial fibrillation (AF), the importance of different aspects of quality of life (QoL), and how we should assess wellbeing.Methods Focus groups of patients with symptomatic permanent AF in a trial of heart rate control; the RATE-AF trial randomised 160 patients aged ≥60 years with permanent AF and at least NYHA class II dyspnoea to either digoxin or beta-blockers. Patient and public representatives led the focus groups and performed all data acquisition and analysis, using thematic approaches to interpret patient views about QoL and its measurement.Results Substantial impairment of health-related QoL was noted in 160 trial patients, with impact on all domains apart from mental health. Eight women and 11 men aged 61–87 years participated in the focus groups. Common themes were a lack of information from healthcare professionals about AF, a lack of focus on QoL in consultations, and a sense of frustration, isolation and reduced confidence. There was marked variability in symptoms in individual patients, with some describing severe impact on activities of daily living, and profound interaction with comorbidities such as arthritis. Day-to-day variation in QoL and difficulty in attributing symptom burden to AF or other comorbidities led to challenges in questionnaire completion. Consensus was reached that collecting both general and AF-specific QoL would be useful in routine practice, along with participation in peer support, which was empowering for the patients.Conclusions The impact of comorbidities is poorly appreciated in the context of AF, with considerable variability in QoL that requires both generic and AF-specific assessment. Improvement in QoL should direct the appraisal, and reappraisal, of treatment decisions for patients with permanent AF.Competing Interest StatementDK reports grants from the National Institute of Health Research (NIHR CDF-2015-08-074 and NIHR HTA-130280), the British Heart Foundation (PG/17/55/33087 and AA/18/2/34218), EU/EFPIA Innovative Medicines Initiative (BigData@Heart 116074) and IRCCS San Raffaele/Menarini and Amomed (Beta-blockers in Heart Failure Collaborative Group NCT0083244); in addition to personal fees from Bayer (Advisory Board), AtriCure (Speaker fees), Amomed (Advisory Board) and Myokardia (Advisory Board), all outside the submitted work. MC receives funding from the NIHR Birmingham Biomedical Research Centre, the NIHR Surgical Reconstruction and Microbiology Research Centre and NIHR ARC West Midlands, Innovate UK (part of UK Research and Innovation), Macmillan Cancer Support, and UCB Pharma; personal fees from Astellas, Takeda, Merck, Daiichi Sankyo, Glaukos, GSK and the Patient-Centered Outcomes Research Institute (PCORI) outside the submitted work. JC reports he has worked with companies that have and are developing anticoagulant drugs, antiarrhythmic therapies and technology for the management of atrial fibrillation. JJ, MS, SH, KB and JM have nothing additional to declare.Clinical Trialclinicaltrials.gov NCT02391337, ISRCTN 95259705 and EudraCT 2015-005043-13Clinical Protocols https://www.birmingham.ac.uk/rate-af Funding StatementThe RATE-AF trial and this focus group work was funded by the National Institute for Health Research (NIHR) as part of a Career Development Fellowship to DK (CDF-2015-08-074). The Patient and Public Involvement in the design and management of the trial was supported by a grant from the West Midlands NIHR Clinical Research Network. The work is also supported by a British Heart Foundation (BHF) Accelerator Award to the University of Birmingham Institute of Cardiovascular Sciences (AA/18/2/34218). The opinions expressed in this paper are those of the authors and do not represent the BHF, NIHR or the UK Department of Health and Social Care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the East Midlands - Derby Research Ethics Committee (16/EM/0178) and the Health Research Authority (IRAS project ID: 191437).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAs per the funders position on sharing of research data, all requests for data should be directed to the Sponsor via the corresponding author. Data access requests from a third party will be managed following the relevant policies and practices of the institution hosting the research, which are expected to be transparent, robust, fair and demonstrate that appropriate mechanisms are in place to provide assurances as to the integrity of the research data. Release of data will be subject to a data use agreement between the institution and the third party requesting the data, which should detail the agreed use and appropriate management of the research data to be shared and include a requirement for recognition of the contribution of the researchers who generated the data and the original funder (UK National Institute for Health Research; policies available at www.nihr.ac.uk).